The role of tryptophan 1072 in human PDE3B inhibitor binding

Biochemical and Biophysical Research Communications

Volumn 307, Issue 4, 2003, Pages 1045-1050

  Chung, Christine ^a   Varnerin, Jeffrey P ^a   Morin, Nancy R ^a   MacNeil, Douglas J ^a   Singh, Suresh B ^a   Patel, Sangita ^a   Scapin, Giovanna ^a   Van Der Ploeg, Lex H T ^b   Tota, Michael R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b MRL San Diego Neuroscience Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAMIDE; MILRINONE; PHOSPHODIESTERASE INHIBITOR; RECOMBINANT ENZYME; RECOMBINANT PHOSPHODIESTERASE 3B; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; CELL INCLUSION; DELETION MUTANT; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME SUBSTRATE; ESCHERICHIA COLI; EXPRESSION VECTOR; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN HYDROLYSIS; PROTEIN LOCALIZATION; RECEPTOR AFFINITY; X RAY CRYSTALLOGRAPHY;

ESCHERICHIA COLI;

EID: 0038444615     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)01299-3     Document Type: Article

References (12)

1. Reinhardt R.R., Chin E., Zhou J., Taira M., Murata T., Manganiello V.C., Bondy C.A. Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases. J. Clin. Invest. 95:1995;1528-1538.
2. Zhang W., Ke H., Tretiakova A.P., Jameson B., Colman R.W. Identification of overlapping but distinct cAMP and cGMP interaction sites with cyclic nucleotide phosphodiesterase 3A by site-directed mutagenesis and molecular modeling based on crystalline PDE4B. Protein Sci. 10:2001;1481-1489.
3. Xu R.X., Hassell A.M., Vanderwall D., Lambert M.H., Holmes W.D., Luther M.A., Rocque W.J., Milburn M.V., Zhao Y., Ke H., Nolte R.T. Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science. 288:2000;1822-1825.
4. Lee M.E., Markowitz J., Lee J.O., Lee H. Crystal structure of phosphodiesterase 4D and inhibitor complex(1). FEBS Lett. 530:2002;53-58.
5. He R., Komas N., Ekholm D., Murata T., Taira M., Hockman S., Degerman E., Manganiello V.C. Expression and characterization of deletion recombinants of two cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE-3). Cell Biochem. Biophys. 29:1998;89-111.
6. Pillai R., Staub S.F., Colicelli J. Mutational mapping of kinetic and pharmacological properties of a human cardiac cAMP phosphodiesterase. J. Biol. Chem. 269:1994;30676-30681.
7. Shakur Y., Takeda K., Kenan Y., Yu Z.X., Rena G., Brandt D., Houslay M.D., Degerman E., Ferrans V.J., Manganiello V.C. Membrane localization of cyclic nucleotide phosphodiesterase 3 (PDE3). Two N-terminal domains are required for the efficient targeting to, and association of, PDE3 with endoplasmic reticulum. J. Biol. Chem. 275:2000;38749-38761.
8. Richter W., Hermsdorf T., Lilie H., Egerland U., Rudolph R., Kronbach T., Dettmer D. Refolding, purification, and characterization of human recombinant PDE4A constructs expressed in Escherichia coli. Protein Expr. Purif. 19:2000;375-383.
9. Dym O., Xenarios I., Ke H., Colicelli J. Molecular docking of competitive phosphodiesterase inhibitors. Mol. Pharmacol. 61:2002;20-25.
10. MacNeil D.J., Occi J.L., Hey P.J., Strader C.D., Graziano M.P. Cloning and expression of a human glucagon receptor. Biochem. Biophys. Res. Commun. 198:1994;328-334.
11. Zhang W., Ke H., Colman R.W. Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis. Mol. Pharmacol. 62:2002;514-520.
12. Pillai R., Kytle K., Reyes A., Colicelli J. Use of a yeast expression system for the isolation and analysis of drug-resistant mutants of a mammalian phosphodiesterase. Proc. Natl. Acad. Sci. USA. 90:1993;11970-11974.